CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration

Annals of Neurology

Volumn 74, Issue 1, 2013, Pages 39-52

  Liachko, Nicole F ^a,b   McMillan, Pamela J ^a,c   Guthrie, Chris R ^a   Bird, Thomas D ^a,b   Leverenz, James B ^a,b,c   Kraemer, Brian C ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Department of Psychiatry and Behavioral Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDC7 PROTEIN; PROTEIN; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FRONTAL LOBE; GENE EXPRESSION REGULATION; HUMANS; MOVEMENT; MUTATION; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; PIPERIDONES; PROTEIN-SERINE-THREONINE KINASES; PYRROLES; RNA, SMALL INTERFERING; SERINE; TDP-43 PROTEINOPATHIES; TRANSFECTION;

EID: 84883297079     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23870     Document Type: Article

References (61)

1. Zhang J, Yang PL, Gray NS,. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
2. Chico LK, Van Eldik LJ, Watterson DM,. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 2009; 8: 892-909.
3. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133.
4. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602-611.
5. Chen-Plotkin AS, Lee VM, Trojanowski JQ,. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 2010; 6: 211-220.
6. Wijesekera LC, Leigh PN,. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009; 4: 3.
7. Cardarelli R, Kertesz A, Knebl JA,. Frontotemporal dementia: a review for primary care physicians. Am Fam Physician 2010; 82: 1372-1377.
8. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256.
9. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268.
10. Hasegawa M, Nonaka T, Tsuji H, et al. Molecular dissection of TDP-43 proteinopathies. J Mol Neurosci 2011; 45: 480-485.
11. Nelson PT, Schmitt FA, Lin Y, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 2011; 134 (pt 5): 1506-1518.
12. Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008; 64: 60-70.
13. Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009; 117: 137-149.
14. Inukai Y, Nonaka T, Arai T, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett 2008; 582: 2899-2904.
15. Liachko NF, Guthrie CR, Kraemer BC,. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci 2010; 30: 16208-16219.
16. Kametani F, Nonaka T, Suzuki T, et al. Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun 2009; 382: 405-409.
17. Iguchi Y, Katsuno M, Takagi S, et al. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol Dis 2012; 45: 862-870.
18. Plowman GD, Sudarsanam S, Bingham J, et al. The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc Natl Acad Sci U S A 1999; 96: 13603-13610.
19. Kamath RS, Fraser AG, Dong Y, et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003; 421: 231-237.
20. Rual JF, Ceron J, Koreth J, et al. Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library. Genome Res 2004; 14: 2162-2168.
21. Wang D, Kennedy S, Conte D, et al. Somatic misexpression of germline P granules and enhanced RNA interference in retinoblastoma pathway mutants. Nature 2005; 436: 593-597.
22. Kraemer BC, Schellenberg GD,. SUT-1 enables tau-induced neurotoxicity in C. elegans. Hum Mol Genet 2007; 16: 1959-1971.
23. Guthrie CR, Schellenberg GD, Kraemer BC,. SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Hum Mol Genet 2009; 18: 1825-1838.
24. Buratti E, Brindisi A, Giombi M, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 2005; 280: 37572-37584.
25. Partridge FA, Tearle AW, Gravato-Nobre MJ, et al. The C. elegans glycosyltransferase BUS-8 has two distinct and essential roles in epidermal morphogenesis. Dev Biol 2008; 317: 549-559.
26. Tomizawa K, Omori A, Ohtake A, et al. Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau. FEBS Lett 2001; 492: 221-227.
27. Sato S, Cerny RL, Buescher JL, Ikezu T,. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem 2006; 98: 1573-1584.
28. Vázquez-Higuera JL, Mateo I, Sánchez-Juan P, et al. Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer's disease. J Alzheimers Dis 2011; 27: 291-297.
29. Yu NN, Yu JT, Xiao JT, et al. Tau-tubulin kinase-1 gene variants are associated with Alzheimer's disease in Han Chinese. Neurosci Lett 2011; 491: 83-86.
30. Houlden H, Johnson J, Gardner-Thorpe C, et al. Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 2007; 39: 1434-1436.
31. Shaye DD, Greenwald I,. OrthoList: a compendium of C. elegans genes with human orthologs. PLoS One 2011; 6: e20085.
32. Bousset K, Diffley JF,. The Cdc7 protein kinase is required for origin firing during S phase. Genes Dev 1998; 12: 480-490.
33. Takahashi TS, Basu A, Bermudez V, et al. Cdc7-Drf1 kinase links chromosome cohesion to the initiation of DNA replication in Xenopus egg extracts. Genes Dev 2008; 22: 1894-1905.
34. Matos J, Lipp JJ, Bogdanova A, et al. Dbf4-dependent CDC7 kinase links DNA replication to the segregation of homologous chromosomes in meiosis I. Cell 2008; 135: 662-678.
35. Costanzo V, Shechter D, Lupardus PJ, et al. An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol Cell 2003; 11: 203-213.
36. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916-919.
37. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442: 920-924.
38. Montagnoli A, Valsasina B, Croci V, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 2008; 4: 357-365.
39. Vanotti E, Amici R, Bargiotti A, et al. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem 2008; 51: 487-501.
40. Fraser AG, Kamath RS, Zipperlen P, et al. Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 2000; 408: 325-330.
41. Lee J, Nam S, Hwang SB, et al. Functional genomic approaches using the nematode Caenorhabditis elegans as a model system. J Biochem Mol Biol 2004; 37: 107-113.
42. Kraemer BC, Burgess JK, Chen JH, et al. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum Mol Genet 2006; 15: 1483-1496.
43. Hamamichi S, Rivas RN, Knight AL, et al. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci U S A 2008; 105: 728-733.
44. Kuwahara T, Koyama A, Koyama S, et al. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum Mol Genet 2008; 17: 2997-3009.
45. Kim BJ, Kim SY, Lee H,. Identification and characterization of human cdc7 nuclear retention and export sequences in the context of chromatin binding. J Biol Chem 2007; 282: 30029-30038.
46. Sato N, Sato M, Nakayama M, et al. Cell cycle regulation of chromatin binding and nuclear localization of human Cdc7-ASK kinase complex. Genes Cells 2003; 8: 451-463.
47. Kim JM, Yamada M, Masai H,. Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development. Mutat Res 2003; 532: 29-40.
48. Oshiro G, Owens JC, Shellman Y, et al. Cell cycle control of Cdc7p kinase activity through regulation of Dbf4p stability. Mol Cell Biol 1999; 19: 4888-4896.
49. Weinreich M, Stillman B,. Cdc7p-Dbf4p kinase binds to chromatin during S phase and is regulated by both the APC and the RAD53 checkpoint pathway. EMBO J 1999; 18: 5334-5346.
50. Ferreira MF, Santocanale C, Drury LS, Diffley JF,. Dbf4p, an essential S phase-promoting factor, is targeted for degradation by the anaphase-promoting complex. Mol Cell Biol 2000; 20: 242-248.
51. Ayala YM, Zago P, D'Ambrogio A, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci 2008; 121 (pt 22): 3778-3785.
52. Zhang YJ, Gendron TF, Xu YF, et al. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener 2010; 5: 33.
53. Brady OA, Meng P, Zheng Y, et al. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem 2011; 116: 248-259.
54. Kabashi E, Lin L, Tradewell ML, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 2010; 19: 671-683.
55. Zhao C, Tovar C, Yin X, et al. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors. Bioorg Med Chem Lett 2009; 19: 319-323.
56. Koltun ES, Tsuhako AL, Brown DS, et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett 2012; 22: 3727-3731.
57. Menichincheri M, Albanese C, Alli C, et al. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem 2010; 53: 7296-7315.
58. Menichincheri M, Bargiotti A, Berthelsen J, et al. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem 2009; 52: 293-307.
59. Shafer CM, Lindvall M, Bellamacina C, et al. 4-(1H-indazol-5-yl)-6- phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett 2008; 18: 4482-4485.
60. Huang C, Tong J, Bi F, et al. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest 2012; 122: 107-118.
61. Manning G,. Genomic overview of protein kinases. WormBook 2005; 13: 1-19.